Any further initiative to pharmacologically modulate the involvement of this protein in the pathogenic pathway of IBD (for example, by blocking CRP-mCRP dissociation or mCRP cell membrane adhesion), could represent a new therapeutic approach able to slow down or inhibit the evolution of intestinal inflammation and to prevent neuroinflammation and the associated risk of dementia. This evidence concerns the gene CRP and inflammatory bowel disease.